Landscape of Biomarker Use in Critically Ill Patients: Systematic Evidence Map of Acute Kidney Injury and Implications for Practice
Authors' conclusion
Substantial clinical evidence assessing the accuracy of biomarkers compared with diagnosis of AKI exists, with fewer practical trials in clinical use.
Study context
- Population
- Critically ill patients; clinical trials and observational studies of novel kidney biomarkers for acute kidney injury (AKI)studies included
- Participants
- 1,116 patients
- Outcome
- Characteristics of included AKI biomarker studies (population, design, clinical context, biomarker purpose)
Methodological detailsmapping review, PubMed/MEDLINE and Embase searched; 6805 records screened
- Mapping review
- PubMed/MEDLINE and Embase searched; 6805 records screened
Main finding
As reported in the abstract
- Adult populations
- 78.6%
- Cohort design
- 93.3%
- Mixed critically ill, cardiac surgery and sepsis contexts
- 69.5%
- Studies to predict AKI
- 944
- Studies to prognosticate clinical outcomes
- 647
- Studies to diagnose AKI etiology
- 109
- Studies to enrich clinical trials
- 6
- Studies to manage AKI
- 12
Original publication
Landscape of Biomarker Use in Critically Ill Patients: Systematic Evidence Map of Acute Kidney Injury and Implications for Practice. Crit Care Med. Published 11 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →